Discover
IMVT
Immunovant, Inc.
29.17
2 x 21.28
2 x 36.85
bid
ask
-
0.47
1.59%
2 @ 04:00 PM
29.17 +0.00 (0.00%)
| Ytd | 14.75% | |
| 1y | 17.53% |
28.75
day range
29.78
21.43
52 week range
45.42
| Open | 29.49 | Prev Close | 29.64 | Low | 28.75 | High | 29.78 | Mkt Cap | 6.03B |
| Vol | 1.17M | Avg Vol | 1.35M | EPS | -2.82 | P/E | N/A | Forward P/E | -10.61 |
| Beta | 0.84 | Short Ratio | 10.91 | Inst. Own | 54.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 34.86 | 200-d Avg | 32.03 | 1yr Est | 48.88 |
| Income Statement | |||
| Operating Expenses | 160.32M | ||
| Research and Development Expense | 142.63M | ||
| Selling, General and Administrative Expense | 17.69M | ||
| Operating Income | -160.32M | ||
| Net Income | -153.22M | ||
| Net Income Common Stock | -153.22M | ||
| Net Income Common Stock (USD) | -153.22M | ||
| Consolidated Income | -153.22M | ||
| Earnings per Basic Share | -0.75 | ||
| Earnings per Basic Share (USD) | -0.75 | ||
| Earnings per Diluted Share | -0.75 | ||
| Earning Before Interest & Taxes (EBIT) | -153.22M | ||
| Earning Before Interest & Taxes (USD) | -153.22M | ||
| Weighted Average Shares | 205.55M | ||
| Weighted Average Shares Diluted | 205.55M | ||
| Balance Sheet | |||
| Cash and Equivalents | 797.80M | ||
| Cash and Equivalents (USD) | 797.80M | ||
| Trade and Non-Trade Receivables | 697.00K | ||
| Current Assets | 851.18M | ||
| Property, Plant & Equipment Net | 351.00K | ||
| Total Assets | 852.49M | ||
| Current Liabilities | 117.10M | ||
| Total Liabilities | 117.10M | ||
| Accumulated Retained Earnings (Deficit) | -1.90B | ||
| Accumulated Other Comprehensive Income | 725.00K | ||
| Shareholders Equity | 735.39M | ||
| Shareholders Equity (USD) | 735.39M | ||
| Assets Non-Current | 1.31M | ||
| Trade and Non-Trade Payables | 10.14M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 119.00K | ||
| Net Cash Flow from Financing | 20.10M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -104.31M | ||
| Issuance (Purchase) of Equity Shares | 20.10M | ||
| Net Cash Flow from Operations | -124.40M | ||
| Effect of Exchange Rate Changes on Cash | -4.00K | ||
| Share Based Compensation | 13.77M | ||